Skip to content
value.today

GABA Therapeutics, Inc.

🇺🇸 Newport Beach, California, USAPharmaceuticalsFounded 2019
Total raised
$22 M
1 round on record
Latest round
$22 M
Aug 2019
First round on record
Aug 2019
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GABA Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2019$22 MNo. 1$10 to $50 million

GABA Therapeutics, Inc.: Raise no. 1, Aug 2019

Investors in this round

2 investors had bought by the notice of Oct 18, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$873,750 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David George Putman · Executive Officer
  • Ian John Massey · Executive Officer, Director
  • Olivier Gregory Dasse · Executive Officer
  • Richard Gregory Farrell · Executive Officer, Director
  • Christian Gregory Fibiger · Director
  • Florian Gregory Brand · Director
  • Matthias Gregory Luz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “GABA Therapeutics, Inc. is subject to certain milestones which are not certain to occur. Upon satisfaction of milestones, an investor has agreed to invest additional funds.”

Signed by Richard Farrell, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 18, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • GABA Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Oct 2019).

    SEC Form D (revenue range) · Oct 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of GABA Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GABA Therapeutics, Inc.
NameRoleNamed in
David George PutmanExecutive officerOct 2019
Ian John MasseyExecutive officerOct 2019
Olivier Gregory DasseExecutive officerOct 2019
Richard Gregory FarrellExecutive officerOct 2019
Christian Gregory FibigerDirectorOct 2019
Florian Gregory BrandDirectorOct 2019
Ian John MasseyDirectorOct 2019
Matthias Gregory LuzDirectorOct 2019
Richard Gregory FarrellDirectorOct 2019